Please enable JavaScript to continue using this application.

Compare $LRMR vs $ZSQR | Chartloom

Compare

$LRMR vs $ZSQR

Larimar Therapeutics Inc · Z Squared Inc (Delaware)

LRMR

Larimar Therapeutics Inc

ZSQR

Z Squared Inc (Delaware)

Compare $LRMR vs $ZSQR

Comparing Larimar Therapeutics Inc and Z Squared Inc (Delaware)

LRMRLarimar Therapeutics Inc

ZSQRZ Squared Inc (Delaware)

LRMRLarimar Therapeutics Inc

Market cap

$277M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-23.1%

52W performance

-44.6%

FCF yield

-56.3%

ZSQRZ Squared Inc (Delaware)

Market cap

$298M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

961.0%

YTD performance

-62.8%

52W performance

-62.8%

FCF yield

-1.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LRMR

ZSQR

Detailed metrics comparison

LRMR

Larimar Therapeutics Inc

ZSQR

Z Squared Inc (Delaware)

Market Cap

LRMR$277M

ZSQR$298M

Enterprise Value

LRMR$185M

ZSQR$283M

Price

LRMR$2.67

ZSQR$5.66

P/E Ratio

LRMRN/A

ZSQRN/A

P/S Ratio

LRMR0.00x

ZSQR106.71x

EV/Sales

LRMR0.00x

ZSQR101.17x

EV/EBITDA

LRMR0.00x

ZSQR0.00x

P/B Ratio

LRMR2.41x

ZSQR1.36x

P/FCF Ratio

LRMRN/A

ZSQRN/A

EV/FCF

LRMR-1.18x

ZSQR-69.99x

PEG Ratio

LRMRN/A

ZSQRN/A

Forward P/E (NTM)

LRMRN/A

ZSQRN/A

Forward P/S (NTM)

LRMRN/A

ZSQRN/A

Revenue (TTM)

LRMR$0

ZSQR$3M

Revenue Growth (YoY)

LRMRN/A

ZSQR961.0%

Forward Rev Growth

LRMR290.4%

ZSQR0.0%

Gross Margin (TTM)

LRMR0.0%

ZSQR-24.6%

Operating Margin (TTM)

LRMR0.0%

ZSQR0.0%

EBITDA Margin (TTM)

LRMR0.0%

ZSQR-712.5%

Net Margin (TTM)

LRMR0.0%

ZSQR-785.1%

FCF Margin (TTM)

LRMRN/A

ZSQR-144.6%

Net Income (TTM)

LRMR$-173M

ZSQR$-22M

FCF (TTM)

LRMR$-156M

ZSQR$-4M

EPS (TTM)

LRMR-$1.66

ZSQR-$0.44

ROE (TTM)

LRMR-13739.0%

ZSQR-5059.0%

ROA (TTM)

LRMR-9765.0%

ZSQR-4757.0%

ROIC (TTM)

LRMR-13739.0%

ZSQR-5038.0%

Cash

LRMR$93M

ZSQR$15M

Debt

LRMR$0

ZSQR$0

Net Cash/Debt

LRMR$93M

ZSQR$15M

Current Ratio (TTM)

LRMR4.70x

ZSQR7.66x

Quick Ratio (TTM)

LRMR4.58x

ZSQR7.64x

Debt/Equity (TTM)

LRMR0.00x

ZSQR0.02x

Debt/Assets (TTM)

LRMR0.0%

ZSQR0.0%

Interest Coverage (TTM)

LRMRN/A

ZSQRN/A

Net Debt/EBITDA (TTM)

LRMR0.00x

ZSQR0.00x

Beta

LRMR0.68

ZSQRN/A

52W Performance

LRMR-44.6%

ZSQR-62.8%

YTD Performance

LRMR-23.1%

ZSQR-62.8%

% from 52W High

LRMR-58.4%

ZSQR-69.9%

% from 52W Low

LRMR2.3%

ZSQR168.2%

Asset Turnover (TTM)

LRMR0.00x

ZSQR0.06x

FCF Yield (TTM)

LRMR-56.3%

ZSQR-1.4%

Earnings Yield (TTM)

LRMR-62.2%

ZSQR-7.4%

Dividend Yield (TTM)

LRMRN/A

ZSQRN/A

Rule of 40

LRMR0.0

ZSQR816.4

EV/GP/RG

LRMRN/A

ZSQRN/A

Ticker research

View LRMR research View ZSQR research

Metric	LRMR Larimar Therapeutics Inc	ZSQR Z Squared Inc (Delaware)
Market & Valuation
Market Cap	$277M	$298M
Enterprise Value	$185M	$283M
Price	$2.67	$5.66
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	106.71x
EV/Sales	0.00x	101.17x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.41x	1.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.18x	-69.99x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$3M
Revenue Growth (YoY)	N/A	961.0%
Forward Rev Growth	290.4%	0.0%
Profitability
Gross Margin (TTM)	0.0%	-24.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-712.5%
Net Margin (TTM)	0.0%	-785.1%
FCF Margin (TTM)	N/A	-144.6%
Net Income (TTM)	$-173M	$-22M
FCF (TTM)	$-156M	$-4M
EPS (TTM)	-$1.66	-$0.44
ROE (TTM)	-13739.0%	-5059.0%
ROA (TTM)	-9765.0%	-4757.0%
ROIC (TTM)	-13739.0%	-5038.0%
Financial Health
Cash	$93M	$15M
Debt	$0	$0
Net Cash/Debt	$93M	$15M
Current Ratio (TTM)	4.70x	7.66x
Quick Ratio (TTM)	4.58x	7.64x
Debt/Equity (TTM)	0.00x	0.02x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.68	N/A
52W Performance	-44.6%	-62.8%
YTD Performance	-23.1%	-62.8%
% from 52W High	-58.4%	-69.9%
% from 52W Low	2.3%	168.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-56.3%	-1.4%
Earnings Yield (TTM)	-62.2%	-7.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	816.4
EV/GP/RG	N/A	N/A
Ticker research	View LRMR research	View ZSQR research

Valuation

P/S Ratio

LRMR

0.00x

ZSQR

106.71x

EV/FCF

ZSQR

-69.99x

LRMR

-1.18x

Growth & revenue

Revenue Growth TTM

ZSQR

961.0%

Forward Revenue Growth

LRMR

290.4%

ZSQR

0.0%

Profitability & performance

Gross Margin

LRMR

0.0%

ZSQR

-24.6%

ROE

ZSQR

-5059.0%

LRMR

-13739.0%

FCF Yield %

ZSQR

-1.4%

LRMR

-56.3%

52-Week Performance

LRMR

-44.6%

ZSQR

-62.8%

Detailed metrics comparison

LRMR

Larimar Therapeutics Inc

ZSQR

Z Squared Inc (Delaware)

Market Cap

LRMR$277M

ZSQR$298M

Enterprise Value

LRMR$185M

ZSQR$283M

Price

LRMR$2.67

ZSQR$5.66

P/E Ratio

LRMRN/A

ZSQRN/A

P/S Ratio

LRMR0.00x

ZSQR106.71x

EV/Sales

LRMR0.00x

ZSQR101.17x

EV/EBITDA

LRMR0.00x

ZSQR0.00x

P/B Ratio

LRMR2.41x

ZSQR1.36x

P/FCF Ratio

LRMRN/A

ZSQRN/A

EV/FCF

LRMR-1.18x

ZSQR-69.99x

PEG Ratio

LRMRN/A

ZSQRN/A

Forward P/E (NTM)

LRMRN/A

ZSQRN/A

Forward P/S (NTM)

LRMRN/A

ZSQRN/A

Revenue (TTM)

LRMR$0

ZSQR$3M

Revenue Growth (YoY)

LRMRN/A

ZSQR961.0%

Forward Rev Growth

LRMR290.4%

ZSQR0.0%

Gross Margin (TTM)

LRMR0.0%

ZSQR-24.6%

Operating Margin (TTM)

LRMR0.0%

ZSQR0.0%

EBITDA Margin (TTM)

LRMR0.0%

ZSQR-712.5%

Net Margin (TTM)

LRMR0.0%

ZSQR-785.1%

FCF Margin (TTM)

LRMRN/A

ZSQR-144.6%

Net Income (TTM)

LRMR$-173M

ZSQR$-22M

FCF (TTM)

LRMR$-156M

ZSQR$-4M

EPS (TTM)

LRMR-$1.66

ZSQR-$0.44

ROE (TTM)

LRMR-13739.0%

ZSQR-5059.0%

ROA (TTM)

LRMR-9765.0%

ZSQR-4757.0%

ROIC (TTM)

LRMR-13739.0%

ZSQR-5038.0%

Cash

LRMR$93M

ZSQR$15M

Debt

LRMR$0

ZSQR$0

Net Cash/Debt

LRMR$93M

ZSQR$15M

Current Ratio (TTM)

LRMR4.70x

ZSQR7.66x

Quick Ratio (TTM)

LRMR4.58x

ZSQR7.64x

Debt/Equity (TTM)

LRMR0.00x

ZSQR0.02x

Debt/Assets (TTM)

LRMR0.0%

ZSQR0.0%

Interest Coverage (TTM)

LRMRN/A

ZSQRN/A

Net Debt/EBITDA (TTM)

LRMR0.00x

ZSQR0.00x

Beta

LRMR0.68

ZSQRN/A

52W Performance

LRMR-44.6%

ZSQR-62.8%

YTD Performance

LRMR-23.1%

ZSQR-62.8%

% from 52W High

LRMR-58.4%

ZSQR-69.9%

% from 52W Low

LRMR2.3%

ZSQR168.2%

Asset Turnover (TTM)

LRMR0.00x

ZSQR0.06x

FCF Yield (TTM)

LRMR-56.3%

ZSQR-1.4%

Earnings Yield (TTM)

LRMR-62.2%

ZSQR-7.4%

Dividend Yield (TTM)

LRMRN/A

ZSQRN/A

Rule of 40

LRMR0.0

ZSQR816.4

EV/GP/RG

LRMRN/A

ZSQRN/A

Ticker research

View LRMR research View ZSQR research

Metric	LRMR Larimar Therapeutics Inc	ZSQR Z Squared Inc (Delaware)
Market & Valuation
Market Cap	$277M	$298M
Enterprise Value	$185M	$283M
Price	$2.67	$5.66
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	106.71x
EV/Sales	0.00x	101.17x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.41x	1.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.18x	-69.99x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$3M
Revenue Growth (YoY)	N/A	961.0%
Forward Rev Growth	290.4%	0.0%
Profitability
Gross Margin (TTM)	0.0%	-24.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-712.5%
Net Margin (TTM)	0.0%	-785.1%
FCF Margin (TTM)	N/A	-144.6%
Net Income (TTM)	$-173M	$-22M
FCF (TTM)	$-156M	$-4M
EPS (TTM)	-$1.66	-$0.44
ROE (TTM)	-13739.0%	-5059.0%
ROA (TTM)	-9765.0%	-4757.0%
ROIC (TTM)	-13739.0%	-5038.0%
Financial Health
Cash	$93M	$15M
Debt	$0	$0
Net Cash/Debt	$93M	$15M
Current Ratio (TTM)	4.70x	7.66x
Quick Ratio (TTM)	4.58x	7.64x
Debt/Equity (TTM)	0.00x	0.02x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.68	N/A
52W Performance	-44.6%	-62.8%
YTD Performance	-23.1%	-62.8%
% from 52W High	-58.4%	-69.9%
% from 52W Low	2.3%	168.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.06x
FCF Yield (TTM)	-56.3%	-1.4%
Earnings Yield (TTM)	-62.2%	-7.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	816.4
EV/GP/RG	N/A	N/A
Ticker research	View LRMR research	View ZSQR research